Ivan Doykov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivan Doykov has a total of 374 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Mills
University College London Great Ormond Street Institute of Child Health Genetics and Genomic Medicine Department London WC1N 1EH
11 shared publications - Wendy E. Heywood
Translational Mass Spectrometry Research Group, Genetic & Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK
11 shared publications Kevin Mills
6 shared publications- Paul Gissen
NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street, London WC1N 3JH, UK
5 shared publications Jenny Hällqvist
Centre for Inborn Errors of Metabolism, UCL Institute of Child Health, London, United Kingdom
4 shared publications- Jenny Hällqvist
University College London Great Ormond Street Institute of Child Health Genetics and Genomic Medicine Department London WC1N 1EH
3 shared publications
Latest Publications
- 11 September 2026
- Published by Elsevier in Biochemical Pharmacology
A novel pipeline for the validation of manganese chelators for the treatment of manganese overload
- 11 September 2026
- Published by Elsevier in Biochemical Pharmacology
A novel pipeline for the validation of manganese chelators for the treatment of manganese overload
- Open Access
- 3 September 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
Inflammation and polyendocrine metabolic ovarian syndrome: utilizing proteomics to unravel this link in adolescents
Purpose and Methods: Polyendocrine metabolic ovarian syndrome (PMOS) affects 10% to 26% of adolescent females. Yet, its pathogenesis is poorly understood. Proteomics is a valuable tool to explore biological pathways underpinning PMOS and identify novel diagnostic/monitoring biomarkers. We undertook deep-phenotyping discovery proteomic profiling (nanoflow 2-dimensional liquid chromatography–quadrupole time-of-flight mass spectrometry with alternating low- and elevated-energy acquisition) on urine samples from a subset of a longitudinal adolescent PMOS cohort (n = 40). We compared the urinary proteome of adolescents (12-19 years, ≥1-year postmenarche) recruited from adolescent endocrinology/gynecology clinics with PMOS or insulin resistance (IR), and community-recruited age-, sex-, and puberty-matched controls. PMOS was defined by adolescent-specific criteria (irregular menstrual cycles and hyperandrogenism). Exclusion criteria included the combined oral contraceptive pill. Results were validated in the whole cohort with a multiplexed targeted proteomic panel. Results: Discovery proteomic analysis identified 3793 proteins, of which 66 were differentially expressed in the PMOS cohort vs IR and controls (candidate PMOS biomarkers). Bioinformatic analysis revealed that almost half of the PMOS-associated biological pathways were related to inflammatory/immunological responses. The inflammatory response was the most significant biological process (P < .001). Targeted proteomic analysis of 89 known inflammatory-associated proteins validated this association. Multivariate analysis demonstrated a distinct inflammatory proteome in adolescent PMOS. Twenty inflammatory-associated proteins were differentially expressed in the PMOS cohort vs IR and control groups, with notable roles in oxidative stress and neuroinflammation. Six proteins were significantly different in PMOS compared with both IR and control cohorts. Conclusion: These analyses provide insight into the pathophysiology of PMOS, highlighting inflammatory processes as a prominent feature of adolescent PMOS and identifying several candidate novel noninvasive biomarkers and drug targets that need further validation.
- 3 September 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
Open AccessInflammation and polyendocrine metabolic ovarian syndrome: utilizing proteomics to unravel this link in adolescents
Purpose and Methods: Polyendocrine metabolic ovarian syndrome (PMOS) affects 10% to 26% of adolescent females. Yet, its pathogenesis is poorly understood. Proteomics is a valuable tool to explore biological pathways underpinning PMOS and identify novel diagnostic/monitoring biomarkers. We undertook deep-phenotyping discovery proteomic profiling (nanoflow 2-dimensional liquid chromatography–quadrupole time-of-flight mass spectrometry with alternating low- and elevated-energy acquisition) on urine samples from a subset of a longitudinal adolescent PMOS cohort (n = 40). We compared the urinary proteome of adolescents (12-19 years, ≥1-year postmenarche) recruited from adolescent endocrinology/gynecology clinics with PMOS or insulin resistance (IR), and community-recruited age-, sex-, and puberty-matched controls. PMOS was defined by adolescent-specific criteria (irregular menstrual cycles and hyperandrogenism). Exclusion criteria included the combined oral contraceptive pill. Results were validated in the whole cohort with a multiplexed targeted proteomic panel. Results: Discovery proteomic analysis identified 3793 proteins, of which 66 were differentially expressed in the PMOS cohort vs IR and controls (candidate PMOS biomarkers). Bioinformatic analysis revealed that almost half of the PMOS-associated biological pathways were related to inflammatory/immunological responses. The inflammatory response was the most significant biological process (P < .001). Targeted proteomic analysis of 89 known inflammatory-associated proteins validated this association. Multivariate analysis demonstrated a distinct inflammatory proteome in adolescent PMOS. Twenty inflammatory-associated proteins were differentially expressed in the PMOS cohort vs IR and control groups, with notable roles in oxidative stress and neuroinflammation. Six proteins were significantly different in PMOS compared with both IR and control cohorts. Conclusion: These analyses provide insight into the pathophysiology of PMOS, highlighting inflammatory processes as a prominent feature of adolescent PMOS and identifying several candidate novel noninvasive biomarkers and drug targets that need further validation.
- Open Access
A Multimodal Multiomics Machine Learning (MMM) approach for biomarker discovery and acceleration of clinical trial readiness for childhood-onset neurological disorders
Background Childhood neurodegenerative disorders are usually rare, genetic, and life-limiting. Whilst targeted approaches present huge potential, significant hurdles include disease rarity, geographical dispersion of patients, funding, clinical trial design, and execution. Crucially, the paucity of robust biomarkers and objective measures of disease progression hampers evaluation of efficacy, drug development and regulatory approval. To address this paradigm, we developed a Multimodal Multiomics Machine Learning (MMM) framework, integrating large-scale, multi-source patient datasets to generate quantitative metrics for disease stratification and longitudinal tracking. We applied MMM to PLA2G6-associated neurodegeneration (PLAN), an ultra-rare condition currently lacking validated biomarkers, where precision gene therapy approaches are at an advanced preclinical stage. Methods A large, single time-point international natural history study (n = 310) was conducted alongside development of a disease-specific rating scale (CoPLAN-DRS), prospective longitudinal neuroimaging, and multiomic biomarker discovery. Machine learning methods were applied to the integrated dataset. Results Kaplan-Meier analyses enabled estimates for survival and time to loss of ambulation. Multiple clinical, radiological, and biofluid biomarkers were identified, clearly correlating with disease progression. The CoPLAN-DRS and brain MRI Quantitative Susceptibility Mapping showed strong positive correlation with age (rho = 0.69, 0.96 respectively). Nicastrin, a critical structural component of the gamma-secretase complex in Amyloid Precursor Protein (APP) processing, was identified as a novel biomarker. Neurofilament light levels showed strong negative correlation with disease progression (rho = -0.74). The complex multi-dimensional dataset was distilled into a simplified, clinically intuitive Digital Disease Dashboard (DDD), enabling real-time visualisation of disease severity. Conclusions Our study highlights the clinical utility of MMM in integrating multi-dimensional data from rare disease cohorts, delivering an unbiased, data-driven, optimised biomarker set. Condensing this into the DDD provides a pragmatically useful tool for clinicians, facilitating longitudinal tracking of disease. The MMM and DDD have accelerated clinical-trial readiness for PLAN, and potentially applicable to a broad range of neurogenetic disorders.
Open AccessA Multimodal Multiomics Machine Learning (MMM) approach for biomarker discovery and acceleration of clinical trial readiness for childhood-onset neurological disorders
Background Childhood neurodegenerative disorders are usually rare, genetic, and life-limiting. Whilst targeted approaches present huge potential, significant hurdles include disease rarity, geographical dispersion of patients, funding, clinical trial design, and execution. Crucially, the paucity of robust biomarkers and objective measures of disease progression hampers evaluation of efficacy, drug development and regulatory approval. To address this paradigm, we developed a Multimodal Multiomics Machine Learning (MMM) framework, integrating large-scale, multi-source patient datasets to generate quantitative metrics for disease stratification and longitudinal tracking. We applied MMM to PLA2G6-associated neurodegeneration (PLAN), an ultra-rare condition currently lacking validated biomarkers, where precision gene therapy approaches are at an advanced preclinical stage. Methods A large, single time-point international natural history study (n = 310) was conducted alongside development of a disease-specific rating scale (CoPLAN-DRS), prospective longitudinal neuroimaging, and multiomic biomarker discovery. Machine learning methods were applied to the integrated dataset. Results Kaplan-Meier analyses enabled estimates for survival and time to loss of ambulation. Multiple clinical, radiological, and biofluid biomarkers were identified, clearly correlating with disease progression. The CoPLAN-DRS and brain MRI Quantitative Susceptibility Mapping showed strong positive correlation with age (rho = 0.69, 0.96 respectively). Nicastrin, a critical structural component of the gamma-secretase complex in Amyloid Precursor Protein (APP) processing, was identified as a novel biomarker. Neurofilament light levels showed strong negative correlation with disease progression (rho = -0.74). The complex multi-dimensional dataset was distilled into a simplified, clinically intuitive Digital Disease Dashboard (DDD), enabling real-time visualisation of disease severity. Conclusions Our study highlights the clinical utility of MMM in integrating multi-dimensional data from rare disease cohorts, delivering an unbiased, data-driven, optimised biomarker set. Condensing this into the DDD provides a pragmatically useful tool for clinicians, facilitating longitudinal tracking of disease. The MMM and DDD have accelerated clinical-trial readiness for PLAN, and potentially applicable to a broad range of neurogenetic disorders.
- Open Access
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (3) , e004448
Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is defined clinically by pathological left ventricular hypertrophy. We have previously developed a plasma proteomics biomarker panel that correlates with clinical markers of disease severity and sudden cardiac death risk in adult patients with HCM. The aim of this study was to investigate the utility of adult biomarkers and perform new discoveries in proteomics for childhood-onset HCM. METHODS: Fifty-nine protein biomarkers were identified from an exploratory plasma proteomics screen in children with HCM and augmented into our existing multiplexed targeted liquid chromatography-tandem/mass spectrometry-based assay. The association of these biomarkers with clinical phenotypes and outcomes was prospectively tested in plasma collected from 148 children with HCM and 50 healthy controls. Machine learning techniques were used to develop novel pediatric plasma proteomic biomarker panels. RESULTS: Four previously identified adult HCM markers (aldolase fructose-bisphosphate A, complement C3a, talin-1, and thrombospondin 1) and 3 new markers (glycogen phosphorylase B, lipoprotein a and profilin 1) were elevated in pediatric HCM. Using supervised machine learning applied to training (n=137) and validation cohorts (n=61), this 7-biomarker panel differentiated HCM from healthy controls with an area under the curve of 1.0 in the training data set (sensitivity 100% [95% CI, 95–100]; specificity 100% [95% CI, 96–100]) and 0.82 in the validation data set (sensitivity 75% [95% CI, 59–86]; specificity 88% [95% CI, 75–94]). Reduced circulating levels of 4 other peptides (apolipoprotein L1, complement 5b, immunoglobulin heavy constant epsilon, and serum amyloid A4) found in children with high sudden cardiac death risk provided complete separation from the low and intermediate risk groups and predicted mortality and adverse arrhythmic outcomes (hazard ratio, 2.04 [95% CI, 1.0–4.2]; P =0.044). CONCLUSIONS: In children, a 7-biomarker proteomics panel can distinguish HCM from controls with high sensitivity and specificity, and another 4-biomarker panel identifies those at high risk of adverse arrhythmic outcomes, including sudden cardiac death.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (3) , e004448
Open AccessNovel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is defined clinically by pathological left ventricular hypertrophy. We have previously developed a plasma proteomics biomarker panel that correlates with clinical markers of disease severity and sudden cardiac death risk in adult patients with HCM. The aim of this study was to investigate the utility of adult biomarkers and perform new discoveries in proteomics for childhood-onset HCM. METHODS: Fifty-nine protein biomarkers were identified from an exploratory plasma proteomics screen in children with HCM and augmented into our existing multiplexed targeted liquid chromatography-tandem/mass spectrometry-based assay. The association of these biomarkers with clinical phenotypes and outcomes was prospectively tested in plasma collected from 148 children with HCM and 50 healthy controls. Machine learning techniques were used to develop novel pediatric plasma proteomic biomarker panels. RESULTS: Four previously identified adult HCM markers (aldolase fructose-bisphosphate A, complement C3a, talin-1, and thrombospondin 1) and 3 new markers (glycogen phosphorylase B, lipoprotein a and profilin 1) were elevated in pediatric HCM. Using supervised machine learning applied to training (n=137) and validation cohorts (n=61), this 7-biomarker panel differentiated HCM from healthy controls with an area under the curve of 1.0 in the training data set (sensitivity 100% [95% CI, 95–100]; specificity 100% [95% CI, 96–100]) and 0.82 in the validation data set (sensitivity 75% [95% CI, 59–86]; specificity 88% [95% CI, 75–94]). Reduced circulating levels of 4 other peptides (apolipoprotein L1, complement 5b, immunoglobulin heavy constant epsilon, and serum amyloid A4) found in children with high sudden cardiac death risk provided complete separation from the low and intermediate risk groups and predicted mortality and adverse arrhythmic outcomes (hazard ratio, 2.04 [95% CI, 1.0–4.2]; P =0.044). CONCLUSIONS: In children, a 7-biomarker proteomics panel can distinguish HCM from controls with high sensitivity and specificity, and another 4-biomarker panel identifies those at high risk of adverse arrhythmic outcomes, including sudden cardiac death.
- Open Access
The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics
Summary: The role of the SNCA gene locus in driving Parkinson’s disease (PD) through rare and common genetic variation is well-recognized, but the transcriptional diversity of SNCA in vulnerable cell types remains unclear. We performed SNCA long-read RNA sequencing in human dopaminergic neurons and show that annotated SNCA transcripts account for only 5% of expression. Rather, the majority of expression (75%) at the SNCA locus originates from transcripts with alternative 5’ and 3’ untranslated regions. Importantly, 10% originates from transcripts encoding open reading frames not previously annotated, which are translated and detectable in human postmortem brain. Defining the 3’ untranslated regions enabled the rational design of antisense oligonucleotides targeting the majority of SNCA transcripts, leading to the effective reversal of PD pathology, including protein aggregation, mitochondrial dysfunction, and toxicity. Resolving the complexity of the SNCA transcriptional landscape impacts RNA therapies and highlights differences in protein isoforms and their contribution to disease.
Open AccessThe diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics
Summary: The role of the SNCA gene locus in driving Parkinson’s disease (PD) through rare and common genetic variation is well-recognized, but the transcriptional diversity of SNCA in vulnerable cell types remains unclear. We performed SNCA long-read RNA sequencing in human dopaminergic neurons and show that annotated SNCA transcripts account for only 5% of expression. Rather, the majority of expression (75%) at the SNCA locus originates from transcripts with alternative 5’ and 3’ untranslated regions. Importantly, 10% originates from transcripts encoding open reading frames not previously annotated, which are translated and detectable in human postmortem brain. Defining the 3’ untranslated regions enabled the rational design of antisense oligonucleotides targeting the majority of SNCA transcripts, leading to the effective reversal of PD pathology, including protein aggregation, mitochondrial dysfunction, and toxicity. Resolving the complexity of the SNCA transcriptional landscape impacts RNA therapies and highlights differences in protein isoforms and their contribution to disease.
- Open Access
- 16 April 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae132
CSF neurofilament light chain profiling and quantitation in neurological diseases
Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid diagnosis and monitor progression and as an outcome measure to assess safety and efficacy of disease-modifying therapies across the clinical translational neuroscience field. Quantitative methods for neurofilament light chain in human biofluids have relied on immunoassays, which have limited capacity to describe the structure of the protein in CSF and how this might vary in different neurodegenerative diseases. In this study, we characterized and quantified neurofilament light chain species in CSF across neurodegenerative and neuroinflammatory diseases and healthy controls using targeted mass spectrometry. We show that the quantitative immunoprecipitation–tandem mass spectrometry method developed in this study strongly correlates to single-molecule array measurements in CSF across the broad spectrum of neurodegenerative diseases and was replicable across mass spectrometry methods and centres. In summary, we have created an accurate and cost-effective assay for measuring a key biomarker in translational neuroscience research and clinical practice, which can be easily multiplexed and translated into clinical laboratories for the screening and monitoring of neurodegenerative disease or acute brain injury.
- 16 April 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 6 (3) , fcae132
Open AccessCSF neurofilament light chain profiling and quantitation in neurological diseases
Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid diagnosis and monitor progression and as an outcome measure to assess safety and efficacy of disease-modifying therapies across the clinical translational neuroscience field. Quantitative methods for neurofilament light chain in human biofluids have relied on immunoassays, which have limited capacity to describe the structure of the protein in CSF and how this might vary in different neurodegenerative diseases. In this study, we characterized and quantified neurofilament light chain species in CSF across neurodegenerative and neuroinflammatory diseases and healthy controls using targeted mass spectrometry. We show that the quantitative immunoprecipitation–tandem mass spectrometry method developed in this study strongly correlates to single-molecule array measurements in CSF across the broad spectrum of neurodegenerative diseases and was replicable across mass spectrometry methods and centres. In summary, we have created an accurate and cost-effective assay for measuring a key biomarker in translational neuroscience research and clinical practice, which can be easily multiplexed and translated into clinical laboratories for the screening and monitoring of neurodegenerative disease or acute brain injury.
- Open Access
- 15 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10177
New Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases
Dried blood spots (DBSs) biomarkers are convenient for monitoring for specific lysosomal storage diseases (LSDs), but they could have relevance for other LSDs. To determine the specificity and utility of glycosphingolipidoses biomarkers against other LSDs, we applied a multiplexed lipid liquid chromatography tandem mass spectrometry assay to a DBS cohort of healthy controls (n = 10) and Gaucher (n = 4), Fabry (n = 10), Pompe (n = 2), mucopolysaccharidosis types I–VI (n = 52), and Niemann–Pick disease type C (NPC) (n = 5) patients. We observed no complete disease specificity for any of the markers tested. However, comparison among the different LSDs highlighted new applications and perspectives of the existing biomarkers. We observed elevations in glucosylceramide isoforms in the NPC and Gaucher patients relative to the controls. In NPC, there was a greater proportion of C24 isoforms, giving a specificity of 96–97% for NPC, higher than 92% for the NPC biomarker N-palmitoyl-O-phosphocholineserine ratio to lyso-sphingomyelin. We also observed significantly elevated levels of lyso-dihexosylceramide in Gaucher and Fabry disease as well as elevated lyso-globotriaosylceramide (Lyso-Gb3) in Gaucher disease and the neuronopathic forms of Mucopolysaccharidoses. In conclusion, DBS glucosylceramide isoform profiling has increased the specificity for the detection of NPC, thereby improving diagnostic accuracy. Low levels of lyso-lipids can be observed in other LSDs, which may have implications in their disease pathogenesis.
- 15 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10177
Open AccessNew Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases
Dried blood spots (DBSs) biomarkers are convenient for monitoring for specific lysosomal storage diseases (LSDs), but they could have relevance for other LSDs. To determine the specificity and utility of glycosphingolipidoses biomarkers against other LSDs, we applied a multiplexed lipid liquid chromatography tandem mass spectrometry assay to a DBS cohort of healthy controls (n = 10) and Gaucher (n = 4), Fabry (n = 10), Pompe (n = 2), mucopolysaccharidosis types I–VI (n = 52), and Niemann–Pick disease type C (NPC) (n = 5) patients. We observed no complete disease specificity for any of the markers tested. However, comparison among the different LSDs highlighted new applications and perspectives of the existing biomarkers. We observed elevations in glucosylceramide isoforms in the NPC and Gaucher patients relative to the controls. In NPC, there was a greater proportion of C24 isoforms, giving a specificity of 96–97% for NPC, higher than 92% for the NPC biomarker N-palmitoyl-O-phosphocholineserine ratio to lyso-sphingomyelin. We also observed significantly elevated levels of lyso-dihexosylceramide in Gaucher and Fabry disease as well as elevated lyso-globotriaosylceramide (Lyso-Gb3) in Gaucher disease and the neuronopathic forms of Mucopolysaccharidoses. In conclusion, DBS glucosylceramide isoform profiling has increased the specificity for the detection of NPC, thereby improving diagnostic accuracy. Low levels of lyso-lipids can be observed in other LSDs, which may have implications in their disease pathogenesis.
- Open Access
- 12 August 2022
- Published by Elsevier in Cell Reports Methods
- Vol. 2 (9) , 100279
Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response
- 12 August 2022
- Published by Elsevier in Cell Reports Methods
- Vol. 2 (9) , 100279
Open AccessQuantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response
- Open Access
- 14 July 2022
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 64 (12) , 1539-1546
Niemann–Pick type C disease as proof‐of‐concept for intelligent biomarker panel selection in neurometabolic disorders
Aim Using Niemann-Pick type C disease (NPC) as a paradigm, we aimed to improve biomarker discovery in patients with neurometabolic disorders. Method Using a multiplexed liquid chromatography tandem mass spectrometry dried bloodspot assay, we developed a selective intelligent biomarker panel to monitor known biomarkers N-palmitoyl-O-phosphocholineserine and 3 beta,5 alpha,6 beta-trihydroxy-cholanoyl-glycine as well as compounds predicted to be affected in NPC pathology. We applied this panel to a clinically relevant paediatric patient cohort (n = 75; 35 males, 40 females; mean age 7 years 6 months, range 4 days-19 years 8 months) presenting with neurodevelopmental and/or neurodegenerative pathology, similar to that observed in NPC. Results The panel had a far superior performance compared with individual biomarkers. Namely, NPC-related established biomarkers used individually had 91% to 97% specificity but the combined panel had 100% specificity. Moreover, multivariate analysis revealed long-chain isoforms of glucosylceramide were elevated and very specific for patients with NPC. Interpretation Despite advancements in next-generation sequencing and precision medicine, neurological non-enzymatic disorders remain difficult to diagnose and lack robust biomarkers or routine functional testing for genetic variants of unknown significance. Biomarker panels may have better diagnostic accuracy than individual biomarkers in neurometabolic disorders, hence they can facilitate more prompt disease identification and implementation of emerging targeted, disease-specific therapies.
- 14 July 2022
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 64 (12) , 1539-1546
Open AccessNiemann–Pick type C disease as proof‐of‐concept for intelligent biomarker panel selection in neurometabolic disorders
Aim Using Niemann-Pick type C disease (NPC) as a paradigm, we aimed to improve biomarker discovery in patients with neurometabolic disorders. Method Using a multiplexed liquid chromatography tandem mass spectrometry dried bloodspot assay, we developed a selective intelligent biomarker panel to monitor known biomarkers N-palmitoyl-O-phosphocholineserine and 3 beta,5 alpha,6 beta-trihydroxy-cholanoyl-glycine as well as compounds predicted to be affected in NPC pathology. We applied this panel to a clinically relevant paediatric patient cohort (n = 75; 35 males, 40 females; mean age 7 years 6 months, range 4 days-19 years 8 months) presenting with neurodevelopmental and/or neurodegenerative pathology, similar to that observed in NPC. Results The panel had a far superior performance compared with individual biomarkers. Namely, NPC-related established biomarkers used individually had 91% to 97% specificity but the combined panel had 100% specificity. Moreover, multivariate analysis revealed long-chain isoforms of glucosylceramide were elevated and very specific for patients with NPC. Interpretation Despite advancements in next-generation sequencing and precision medicine, neurological non-enzymatic disorders remain difficult to diagnose and lack robust biomarkers or routine functional testing for genetic variants of unknown significance. Biomarker panels may have better diagnostic accuracy than individual biomarkers in neurometabolic disorders, hence they can facilitate more prompt disease identification and implementation of emerging targeted, disease-specific therapies.
- Open Access
- 1 March 2021
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 194, 111426
A geroscience approach for Parkinson’s disease: Conceptual framework and design of PROPAG-AGEING project
- 1 March 2021
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 194, 111426
Open AccessA geroscience approach for Parkinson’s disease: Conceptual framework and design of PROPAG-AGEING project